ImmunoMet Therapeutics Appoints Benjamin R. Cowen, PhD, MBA, Chief Operating Officer > Investors & Media

본문 바로가기


Investors & Media

ImmunoMet Therapeutics Appoints Benjamin R. Cowen, PhD, MBA, Chief Operating Officer

Date :
November 29, 2016

news_logo.png


ImmunoMet Therapeutics Appoints Benjamin R. Cowen,

PhD, MBA, Chief Operating Officer  

 

Houston, TX, November 29, 2016 -- ImmunoMet Therapeutics, a development stage

biotechnology company focused on utilizing cellular metabolism to develop novel

cancer and immuno-oncology therapies, today announced the appointment of

Benjamin R. Cowen as Chief Operating Officer. Dr. Cowen brings more than 20

years of biotechnology and pharmaceutical experience in business development, 

inance, R&D portfolio management, and strategic planning. 

 

Sung-wuk Kim, Chief Executive Officer at ImmunoMet Therapeutics, said, “We are

pleased to welcome Ben Cowen to the Company, as we are building our

management team in the United States. Ben’s proven track record and his broad

experience will be valuable to the Company, and we look forward to his

contributions toward our future success. This is an important time for the

Company, as we expect to begin our Phase 1 study of IM156, a mitochondrial

OXPHOS inhibitor, in early 2017 and rapidly move forward with the development of

IM188, our immuno-oncology program, that targets immune suppressor cells.”

 

"I am pleased to join ImmunoMet and to work with the management team to

advance the Company’s development programs and collaborate with potential

partners on IM188 and IM156, which are based on our novel technology in the areas

of immuno-oncology and immune cell metabolism,” said Dr. Cowen. "I am

enthusiastic about the potential of the Company’s pipeline and the benefit it may

provide patients who suffer from difficult-to-treat, drug resistant and relapse

cancers.”  

 

Dr. Cowen most recently served as the Vice President of Corporate Development at

Milestone Pharmaceuticals, where he played a key role in a Series B financing and

was responsible for business development. Dr. Cowen has significant experience

working with private, early-stage biotechnology companies

and public companies including, Shire and Merck, where he held several management positions and

received recognition for leading high-performance teams and successfully

completing key business development transactions. Dr. Cowen received his Ph.D.

from University of Illinois at Urbana Champaign, his MBA from Carnegie Mellon

University, and his BA at Brandeis University.  

 

About ImmunoMet Therapeutics

ImmunoMet Therapeutics, a development stage biotechnology company, is

dedicated to developing innovative oncology products to improve the quality of

life and make a meaningful difference in the lives of cancer patients. The

Company, a spinoff of HanAll BioPharma and headquartered in Houston, is focused

on immuno-oncology targeting immune suppressor cells (ISC) and immune cell

metabolism, which are designed to enhance anti-cancer immunity, disrupt cancer

cell growth, and reverse immunosuppression in tumor microenvironments. The

Company’s novel technology addresses the high unmet medical need to treat drug

resistant, relapse cancers and improve response rates of immuno-oncology

treatments. For more information about the Company, please visit

www.immunomet.com. 

 

Contact

Joseph T. Schepers:  919-616-1923, joeschepers@immunomet.com 


Copyright © ImmunoMet. All rights reserved.